Investor Presentation: July 2023

OTCQB:LADX

CORPORATE OVERVIEW

July 2023

Non-Confidential

LadRx Corporation Safe Harbor Statement

THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. SUCH STATEMENTS MAY BE PRECEDED BY THE WORDS "INTENDS," "MAY," "WILL," "PLANS," "EXPECTS," "ANTICIPATES," "PROJECTS," "PREDICTS," ESTIMATES," "AIMS," "BELIEVES," "HOPES," "POTENTIAL"

OR SIMILAR WORDS. FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF MANAGEMENT AS WELL AS CERTAIN ASSUMPTIONS MADE BY AND INFORMATION CURRENTLY AVAIALABLE TO MANAGEMENT, ARE NOT GUARANTEES OF FUTURE PERFORMANCE, AND ARE SUBJECT TO VARIOUS KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES, MANY OF WHICH ARE BEYOND LADRX'S CONTROL, AND CANNOT BE PREDICTED OR QUANTIFIED AND CONSEQUENTLY, RESULTS MAY DIFFER MATERIALLY FROM THOSE EXPRESSED OR IMPLIED BY SUCH FORWARD-LOOKING STATEMENTS AS A RESULT OF VARIOUS RISKS AND UNCERTAINTIES, INCLUDING THOSE RISK FACTORS DISCUSSED IN THE ANNUAL AND QUARTERLY REPORTS THAT LADRX FILES WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION. STATEMENTS CONTAINED HEREIN ARE MADE AS OF THE DATE OF THIS PRESENTATION UNLESS STATED OTHERWISE, AND NEITHER THIS PRESENTATION, NOR ANY SALE OF SECURITIES, SHALL UNDER ANY CIRCUMSTANCES CREATE AN IMPLICATION THAT THE INFORMATION CONTAINED HEREIN IS CORRECT AS OF ANY TIME AFTER SUCH DATE OR THAT INFORMATION WILL BE UPDATED OR REVISED TO REFLECT INFORMATION THAT SUBSEQUENTLY BECOMES AVAILABLE OR CHANGES OCCURRING AFTER THE DATE HEREOF. LADRX RESERVES THE RIGHT TO UPDATE, AMEND OR SUPPLEMENT THE INFORMATION AT ANY TIME IN ITS ABSOLUTE DISCRETION (WITHOUT INCURRING ANY OBLIGATION TO DO SO). INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THESE DOCUMENTS FREE OF CHARGE ON THE SEC'S WEB SITE AT WWW.SEC.GOV. LADRX ASSUMES NO OBLIGATION TO PUBLICLY UPDATE OR REVISE ITS FORWARD-LOOKING STATEMENTS AS A RESULT OF NEW INFORMATION, FUTURE EVENTS OR OTHERWISE.

Management and Board

Stephen Snowdy, PhD

CEO

• Recently joined LadRx
• PhD Neurobiology University of North Carolina
• Full-cycleexperience: napkin drawings to global product launch
• 20 years of experience in medical executive management
• • Venture capital
  • Medical devices
  • Pharma
  • IPO
  • Public company management

Gilad Gordon, MD R&D/Regulatory Consultant

• Oncology development expert
• 30 years experience developing cancer treatments
• Directly responsible for 50 INDs, hundreds of clinical trials

John Caloz

CFO

• 30+ years of CFO experience in life sciences sector
• Occulogix, IRIS Int'l, Synarc, Phoenix Int'l Life
  Sciences

Board of Directors

• Jennifer Simpson, PhD

LadRx Chair of the Board. CEO of Panbela Therapeutics. Former CEO of Delcath, Oncology Lead at Imclone, Product Director Oncology Marketing at Ortho Biotech

• Joel Caldwell

Chair of Audit Committee. 30 years of experience in tax, finance, and auditing.

• Cary J. Claiborne

Chair of the Compensation Committee. CEO of Adial Pharmaceuticals Inc. Former CEO of Prosperity Capital Management, LLC.

Despite Progress, Cancer is a Massive Burden

In 2019, cancer claimed over 10 million lives worldwide1

Leading attributable causes (approx. half of cancers are attributable) are smoking, alcohol use, and high BMI1

Cancer is the second leading cause of death in the US, behind heart disease2

Graphs Adapted from Center for Disease Control, "An Update on Cancer in the United States"

1. "The Global Burden of Cancer…", The Lancet. August 20, 2022. 400:10352. 563-591
2. Center for Disease Control, "An Update on Cancer in the United States"

Investment Highlights

LadRx has developed elegant tumor targeting and release molecules called LADR that are based on small molecular entities (no complex antibodies or nanoparticles) allowing for higher dosing and lower off-target tox

• First LADR drug Aldoxorubicin was licensed to Immunity Bio and is in human trial for pancreatic cancer
• Next-genLADR-based drugs are nearing readiness for IND
• Small and virtual to minimize cash use
• Strong, broad, and global patent portfolio